ahlam1399
09-26-2016, 12:40 PM
Sa**fi may win U.S. approval of $3 billion eczema drug by March
(Reuters) - French drugmaker Sa**fi *and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=9vZCybgV7VY:0hg6T6KN0KU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9vZCybgV7VY:0hg6T6KN0KU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=9vZCybgV7VY:0hg6T6KN0KU:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9vZCybgV7VY:0hg6T6KN0KU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=9vZCybgV7VY:0hg6T6KN0KU:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/9vZCybgV7VY
(Reuters) - French drugmaker Sa**fi *and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=9vZCybgV7VY:0hg6T6KN0KU:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9vZCybgV7VY:0hg6T6KN0KU:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=9vZCybgV7VY:0hg6T6KN0KU:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=9vZCybgV7VY:0hg6T6KN0KU:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=9vZCybgV7VY:0hg6T6KN0KU:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/9vZCybgV7VY